Massive NIH–industry project opens portals to target validation

Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.

Search for this author in:

Credit: Image modified from normaals/iStock/Getty Images Plus

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 18, 240-242 (2019)

doi: 10.1038/d41573-019-00033-8

Updates & Corrections

  • Clarification 01 March 2019: Clarifications have been made about Regeneron's use of the diabetes portal and about the number of exomes needed to account for more of the genetic underpinnings of diabetes.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.